carbostyril has been researched along with Multiple Myeloma in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 14 (56.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, J; Geng, X; Liu, L; Wang, T; Zhang, J | 1 |
| Breckpot, K; Chantry, A; De Beule, N; De Bruyne, E; De Veirman, K; Eriksson, H; Evans, H; Fan, R; Hose, D; Maes, A; Maes, K; Menu, E; Muylaert, C; Satilmis, H; Törngren, M; Vanderkerken, K; Vandewalle, N; Verheye, E; Vlummens, P | 1 |
| Jakubowiak, AJ; Johnson, D; Nakamura, Y; Park, JH; Rosebeck, S; Stefka, AT | 1 |
| Jung, JI; Kim, J; Kim, SA; Lee, Y; Park, KY | 1 |
| Sebestyén, Z; Szabó, B; Szepesi, K | 1 |
| Beksac, M; Cai, C; Callander, N; Kalimi, G; Reece, D; Scheid, C; Scott, JW; Shi, M; Sonneveld, P; Spencer, A; Stewart, AK | 1 |
| Bae, KJ; Byun, BJ; Chon, HJ; Kim, J; Kim, SA; Lee, Y | 1 |
| Ashihara, E; Chauhan, J; Fletcher, S; Imayoshi, N; Nakata, S; Strovel, JW; Takata, K; Toda, Y; Yoshioka, M | 1 |
| Almenara, JA; Chen, S; Dai, Y; Dent, P; Grant, S; Kramer, LB; Pei, XY; Venditti, CA | 1 |
| Boise, LH; Chen, J; David, E; Flowers, CR; Kaufman, JL; Lonial, S; Marcus, AI; Schafer-Hales, K; Sun, SY; Torre, C | 1 |
| Beaupre, DM; Buzzeo, RW; Cuevas, J; Gabriel, M; Hazlehurst, LA; Mari, Y; Yanamandra, N | 1 |
| Amiot, M; Bataille, R; Harousseau, JL; Le Gouill, S; Pellat-Deceunynck, C; Rapp, MJ; Robillard, N | 1 |
| Albitar, M; Cortes, J; Garcia-Manero, G; Giles, F; Kantarjian, H; Koller, C; Kurzrock, R; O'Brien, S; Rackoff, W; Talpaz, M; Thibault, A; Thomas, D | 1 |
| Ashihara, E; Fuchida, S; Fujita, N; Inaba, T; Matsubara, H; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R | 1 |
| Adjei, AA; Ahmann, G; Alsina, M; Belle, AN; Bruzek, LM; Cantor, AB; Dalton, WS; Djulbegovic, B; Fonseca, R; Gerbino, E; Greipp, PR; Kaufmann, SH; Overton, RM; Price-Troska, T; Sebti, SM; Sullivan, D; Wilson, EF; Wright, JJ | 1 |
| Beaupre, DM; Boise, LH; Cepero, E; Lichtenheld, MG; Obeng, EA | 1 |
| Chang, H; Chen, C; Heise, C; Li, ZH; Reece, D; Stewart, AK; Trudel, S; Wei, E; Wiesmann, M | 1 |
| Iida, S | 1 |
| Alsina, M; Beam, C; Beaupre, DM; Dalton, W; Gerbino, E; Hamilton, AD; Kerr, WG; Lichtenheld, MG; Mackley, PA; Muro-Cacho, C; Sebti, SM; Zhu, K | 1 |
| Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R | 1 |
| Ashihara, E; Fuchida, S; Inaba, T; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R; Yamada, N | 1 |
| Beaupre, DM; Boulware, D; Buzzeo, RW; Colaco, NM; Dalton, WS; Parquet, NA; Perez, LE; Wright, G; Yanamandra, N | 1 |
| Abrams, TJ; Embry, MG; Garrett, EN; Heise, CC; Hollenbach, PW; Jallal, B; Mendel, DB; Oei, YA; Pryer, NK; Rendahl, KG; Swinarski, DE; Tang, Y; Trudel, S; Xin, X | 1 |
| Ager, S; Baglin, TP; Barker, P; Bass, G; Jacobson, SK; Johnson, D; Mahendra, P; Marcus, RE | 1 |
2 review(s) available for carbostyril and Multiple Myeloma
| Article | Year |
|---|---|
[Pharmaceutical applications of sulfobuthylether-beta-cyclodextrin].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Antiemetics; Antifungal Agents; Antipsychotic Agents; Aripiprazole; beta-Cyclodextrins; Chemistry, Pharmaceutical; Dosage Forms; Drug Stability; Humans; Hungary; Multiple Myeloma; Oligopeptides; Piperazines; Pyrimidines; Quinolones; Quinuclidines; Solubility; Thiazoles; Triazoles; Voriconazole | 2013 |
[Multiple myeloma: from molecular pathogenensis to the development of molecular targeting therapies].
Topics: Antineoplastic Agents; Chromosomal Instability; Chromosome Deletion; Enzyme Inhibitors; Humans; Multiple Myeloma; Quinolones; Signal Transduction | 2004 |
3 trial(s) available for carbostyril and Multiple Myeloma
| Article | Year |
|---|---|
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 4; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protein Kinase Inhibitors; Quinolones; Recurrence; Retreatment; Translocation, Genetic; Treatment Outcome | 2015 |
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Blast Crisis; Drug Administration Schedule; Drug Eruptions; Endothelial Growth Factors; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphokines; Male; Middle Aged; Multiple Myeloma; Nausea; Neoplasm Proteins; Primary Myelofibrosis; Quinolones; Salvage Therapy; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Carrier Proteins; Cell Survival; Disease Progression; DNA-Binding Proteins; Farnesyltranstransferase; Female; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multiple Myeloma; Phosphorylation; Protein Prenylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinolones; ras Proteins; Salvage Therapy; Signal Transduction; STAT3 Transcription Factor; Trans-Activators | 2004 |
20 other study(ies) available for carbostyril and Multiple Myeloma
| Article | Year |
|---|---|
Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c-Myc G-Quadruplex Stabilizers to Suppress c-Myc Transcription and Myeloma Growth.
Topics: Aminopyridines; DNA; Fluoroquinolones; Humans; Indans; Molecular Docking Simulation; Multiple Myeloma; Naphthyridines; Oxadiazoles; Quinolones; RNA, Messenger | 2022 |
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
Topics: Animals; Bone Resorption; Cell Proliferation; Humans; Immunosuppressive Agents; Mice; Multiple Myeloma; Myeloid Cells; Quinolones; Tumor Microenvironment | 2023 |
Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; Female; Humans; Lenalidomide; Leukocytes, Mononuclear; Mice; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Primary Cell Culture; Protein Kinase Inhibitors; Quinolones; Thiophenes; Xenograft Model Antitumor Assays | 2020 |
Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells.
Topics: Aniline Compounds; Apoptosis; Benzimidazoles; beta Catenin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Germinal Center Kinases; Humans; Interleukin-6; Multiple Myeloma; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinolones; Thiazoles; Wnt Signaling Pathway | 2017 |
Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Benzimidazoles; beta Catenin; Cell Line, Tumor; Cell Proliferation; Germinal Center Kinases; Humans; Multiple Myeloma; Neoplasm Proteins; Protein Serine-Threonine Kinases; Quinolones; Wnt Signaling Pathway | 2016 |
CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Enhancer Elements, Genetic; Genes, myc; Humans; Mice; Multiple Myeloma; Nuclear Proteins; Promoter Regions, Genetic; Quinolones; Survival Analysis; Transcription Factors | 2017 |
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Checkpoint Kinase 1; DNA Damage; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Multiple Myeloma; Protein Kinase Inhibitors; Protein Kinases; Quinolones; ras Proteins; Staurosporine; Xenograft Model Antitumor Assays | 2008 |
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Quinolones; Ubiquitination | 2010 |
Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Calcium Channels; Cell Membrane; Endoplasmic Reticulum; Farnesyltranstransferase; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinolones; Tumor Cells, Cultured; U937 Cells | 2011 |
Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells.
Topics: Aged; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; Cell Division; DNA-Binding Proteins; Enzyme Inhibitors; Farnesyltranstransferase; Female; Flow Cytometry; Humans; Interleukin-6; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Multiple Myeloma; Protein Prenylation; Quinolones; STAT3 Transcription Factor; Trans-Activators; Tumor Cells, Cultured | 2002 |
Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Cell Separation; Dose-Response Relationship, Drug; Farnesyltranstransferase; Humans; Multiple Myeloma; Mutation; Quinolones; ras Proteins; Tumor Cells, Cultured | 2003 |
R115777 induces Ras-independent apoptosis of myeloma cells via multiple intrinsic pathways.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Caspase 9; Caspase Inhibitors; Caspases; CCAAT-Enhancer-Binding Proteins; Cell Division; Cell Line, Tumor; Humans; Intracellular Membranes; Membrane Potentials; Membrane Proteins; Mitochondria; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Protein Prenylation; Proto-Oncogene Proteins c-bcl-2; Quinolones; ras Proteins; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Signal Transduction; Transcription Factor CHOP; Transcription Factors | 2004 |
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
Topics: Animals; Benzimidazoles; Cell Division; Cell Line, Tumor; Cell Transformation, Neoplastic; Dexamethasone; Drug Interactions; Female; Glucocorticoids; Humans; Insulin-Like Growth Factor I; Interleukin-6; Macrophage Colony-Stimulating Factor; Mice; Mice, Inbred Strains; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolones; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; Stromal Cells; Xenograft Model Antitumor Assays | 2005 |
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow Cells; Caspase 3; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials as Topic; Cytochromes c; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme Activation; Farnesyltranstransferase; Flow Cytometry; Fluorouracil; G2 Phase; Gemcitabine; Homozygote; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Mice; Mice, SCID; Mitosis; Multiple Myeloma; Paclitaxel; Quinolones; Taxoids; Tetrazolium Salts; Thiazoles | 2005 |
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin | 2005 |
Nitrogen-containing bisphosphonate incadronate augments the inhibitory effect of farnesyl transferase inhibitor tipifarnib on the growth of fresh and cloned myeloma cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Humans; Multiple Myeloma; Quinolones; Tumor Cells, Cultured | 2005 |
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fibronectins; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Pyrazines; Quinolones; Stromal Cells; Tumor Cells, Cultured | 2006 |
CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
Topics: Adaptor Proteins, Signal Transducing; Animals; Benzimidazoles; Cell Growth Processes; Cell Line, Tumor; Enzyme Inhibitors; Humans; Membrane Proteins; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Phosphorylation; Protein-Tyrosine Kinases; Quinolones; Receptor, Fibroblast Growth Factor, Type 3; Xenograft Model Antitumor Assays | 2006 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous | 2007 |
Short-course intravenous antibiotics with oral quinolone prophylaxis in the treatment of neutropenic fever in autologous bone marrow or peripheral blood progenitor cell transplant recipients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacteremia; Bone Marrow Transplantation; Female; Fever; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neutropenia; Pseudomonas aeruginosa; Quinolones; Staphylococcus; Streptococcus; Transplantation, Autologous | 1996 |